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Abstract
IMPORTANCE Advanced glycation end products (AGEs) and their receptor (RAGE) are implicated in
the pathophysiological processes of dementia and potentially underlie the association of diabetes
with neurodegeneration. However, longitudinal studies examining this association are lacking.
OBJECTIVE To determine whether markers of the AGE-RAGE system are associated with prevalent
and incident dementia and with cognition.
DESIGN, SETTING, AND PARTICIPANTS In this population-based cohort study including
participants from the prospective Rotterdam Study, extracellular newly identified RAGE binding
protein (EN-RAGE) and soluble RAGE (S-RAGE) were measured in plasma collected between 1997
and 1999 in a random selection of participants, and additionally in participants with prevalent
dementia. Participants without dementia were followed up for dementia until 2016. Skin AGEs,
measured as skin autofluorescence, and cognition were measured between 2013 and 2016 in
participants without dementia. Data analysis was performed from June 2019 to December 2019.
EXPOSURES EN-RAGE, S-RAGE, and skin autofluorescence.
MAIN OUTCOMES AND MEASURES Prevalent and incident dementia and cognition, adjusted for
potential confounders, including age, sex, diabetes, educational level, APOE ε4 carrier status,
smoking, and estimated glomerular filtration rate.
RESULTS Of 3889 included participants (mean [SD] age, 72.5 [8.9] years; 2187 [56.2%] women),
1021 participants had data on plasma markers (mean [SD] age 73.6 [7.8] years; 564 [55.2%] women),
73 participants had dementia at baseline, and during 10 711 person-years of follow-up, 161
participants developed incident dementia. Compared with low levels, high EN-RAGE level was
associated with a higher prevalence of dementia (odds ratio [OR], 3.68 [95% CI, 1.50-8.03];
P = .003), while high S-RAGE level was associated with a lower prevalence of dementia (OR, 0.37
[95% CI, 0.17-0.78]; P = .01). These associations attenuated in a longitudinal setting, with hazard
ratios of 0.65 (95% CI, 0.42-1.01) for high EN-RAGE (P = .05) and 1.22 (95% CI, 0.82-1.81) for high
S-RAGE (P = .33). Among 2890 participants without dementia (mean [SD] age, 72.5 [9.4] years;
1640 [57%] women), higher skin autofluorescence was associated with lower global cognitive
function (adjusted difference in z score per 1-SD higher skin autofluorescence, −0.07 [95% CI, −0.11
to −0.04]), especially among carriers of the APOE ε4 allele (adjusted difference in z score per 1-SD
higher skin autofluorescence, −0.15 [95% CI, −0.22 to −0.07]).
CONCLUSIONS AND RELEVANCE These findings suggest that the AGE-RAGE system is associated
with cognitive decline and dementia cross-sectionally but not longitudinally. This indicates either a
short-term association or reverse causality. Findings of cross-sectional associations between higher
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Key Points
Question Are advanced glycation end
products (AGEs) and their receptor
(RAGE) associated with cognition and
dementia?
Findings In this cohort study among
3889 adults from the general Dutch
population, markers of RAGE in plasma
were associated with prevalent
dementia in 1021 participants but were
not associated with the incidence of
dementia after a maximum of 18.7 years
of follow-up. Skin AGEs were cross-
sectionally associated with worse
cognition in 2890 individuals.
Meaning These findings suggest that
AGEs and RAGE were associated with
the pathophysiological processes of
cognitive decline and dementia,
although their role in the long term
should be further clarified.
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Abstract (continued)
skin autofluorescence and lower cognitive function and an association with APOE status also warrant
replication and prospective studies.
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Introduction
Diabetes is an established risk factor for dementia, but the exact mechanism remains unclear.1
Accelerated formation of advanced glycation end products (AGEs) has been proposed as a link.2
AGEs are a group of molecules generated nonenzymatically by attaching sugars to proteins, lipids, or
nucleic acids and lead to modification and cross-linking of proteins.3 Furthermore, activation of the
AGE receptor (RAGE) by AGEs or by other RAGE ligands, including amyloid-β, results in an
inflammatory response and subsequently to upregulation of the receptor.4
Accumulation of AGEs takes place throughout life, especially in long-lived tissues. Excessive
accumulation is observed in conditions of hyperglycemia and oxidative and inflammatory stress and
is involved in diabetes, chronic kidney disease, and diseases associated with old age, including
Alzheimer disease (AD).5-7 AGEs colocalize with AD-associated proteins in the brain, such as tau,
neurofibrillary tangles, and amyloid-β.7-9 RAGE is also implicated in the pathophysiological processes
of dementia and is thought to play a role in cerebral amyloid-β accumulation by facilitating its
transport through the blood-brain barrier, as well as in neuronal degeneration and in the formation
of fibrous tangles.10 Previous studies have found upregulation of RAGE expression in the brains of
patients with AD.11-15 Furthermore, a recent study showed that markers of the AGE-RAGE system
differ with APOE (OMIM 107741) ε4 carrier status, a genetic risk factor associated with dementia.16
AGEs can be measured in the skin using skin autofluorescence, a proxy associated with
accumulation of AGEs in long-lived tissues, including the brain.17,18 Circulating molecules that are
involved in the AGE-RAGE system include extracellular newly identified RAGE-binding protein
(EN-RAGE), a RAGE ligand that has been associated with several chronic inflammatory diseases and
coronary heart disease,19,20 and the soluble form of RAGE (S-RAGE), which acts as a decoy for RAGE
ligands and may have an anti-inflammatory effect.21
To our knowledge, no studies have provided longitudinal information about the association of
the AGE-RAGE system with dementia. To address this knowledge gap, we examined the association
of plasma levels of EN-RAGE and S-RAGE with dementia cross-sectionally and longitudinally and the
association of skin autofluorescence with cognition cross-sectionally.
Methods
Study Setting
This study was conducted within the Rotterdam Study, a prospective population-based cohort study
that initiated in 1989 with 7983 participants aged 55 years and older (RS-I). As a second recruitment
wave, 3011 new participants aged 55 years and older participated from 2000 onwards (RS-II).
Another 3932 participants aged 45 years and older participated from 2006 onwards (RS-III).
Follow-up examinations at the research center take place every 4 to 6 years. The objectives and
further details of the study have been described elsewhere.22,23
This study follows the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guideline. The Rotterdam Study has been approved by the medical ethics
committee of the Erasmus University Medical Center and by the review board of the Netherlands
Ministry of Health, Welfare and Sports. All participants provided written informed consent.
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Study Population
EN-RAGE and S-RAGE were measured in plasma collected between 1997 and 1999 from a random
subset of 964 participants of RS-I, and additionally of 57 participants with dementia (eFigure 1 in the
Supplement). Skin autofluorescence was measured between 2013 and 2016 in 3009 participants
from all 3 cohort waves. Of these, 2890 participants did not have dementia and underwent cognitive
tests (eFigure 2 in the Supplement). Skin autofluorescence and cognitive test scores outside of the
mean and 4 SDs range were considered outlying values and excluded from the analyses.
Measurement of EN-RAGE and S-RAGE
Fasting blood samples were collected at the research center. Plasma was isolated and immediately
put on ice and stored at −80 °C. Citrate plasma (200 μL) was sent in July 2008 to Rules-Based
Medicine (Myriad RBM), where EN-RAGE and S-RAGE were assessed using multiplex immunoassay
on a custom-designed human multianalyte profile. The intra-assay variability was less than 4%, and
the interassay variability was less than 13%.
Measurement of Skin Autofluorescence
During the visit to the research center, skin autofluorescence was measured at the inner side of the
dominant forearm using the AGE Reader device (DiagnOptics) based on the fluorescent property of
AGEs.24 The device has been validated against AGEs measured in skin biopsies from the same site
where skin autofluorescence was measured.17 Participants were asked not to use skin creams before
the measurement. The mean of 3 consecutive measurements was used for analyses.
Assessment of Dementia
The Mini-Mental State Examination and the Geriatric Mental Schedule organic level were used to
screen for dementia at baseline and subsequent center visits.25 Cutoffs were less than 26 for the
Mini-Mental State Examination and greater than 0 for the Geriatric Mental Schedule. Participants
with a positive screening outcome underwent further testing using the Cambridge Examination for
Mental Disorders of the Elderly. Additionally, the electronic medical records from general
practitioners and the regional institute for outpatient mental health care were used for the dementia
diagnosis. The final diagnosis was established by a consensus panel led by a consultant neurologist,
according to standard criteria for dementia (using Diagnostic and Statistical Manual of Mental
Disorders [Third Edition Revised]26) and AD (using National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer Disease and Related Disorders Association27).
Cognitive Test Battery and General Cognition
During center visits, participants underwent a battery of cognitive function examinations assessing
various cognitive domains, including the Letter Digit Substitution Task, the Stroop test, and the Word
Fluency Test for executive function; the 15-Word Learning Test for memory; and the Purdue
Pegboard test for fine motor skill.28 For tests consisting of subtasks, the interference task of the
Stroop test, the delayed recall task of the Word Learning Test, and the sum score of all 3 tasks of the
Purdue Pegboard were used for analyses.
Assessment of Covariates
Information on alcohol use, smoking status, and educational level was obtained during structured
home interviews.22,29 Body mass index was calculated as weight in kilograms divided by height in
meters squared. Blood pressure was measured in the sitting position on the right arm using a
random-zero sphygmomanometer. Serum concentrations of total cholesterol, high-density
lipoprotein cholesterol, triglycerides, glucose, and creatinine were measured in fasting blood
samples. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney
Disease Epidemiology Collaboration equation.22,30 APOE was genotyped by polymerase chain
reaction in RS-I and by biallelic TaqMan assay in RS-II and RS-III.31,32 Participants were categorized as
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carries of 0, 1, or 2 ε4 alleles according to the APOE genotype. Diabetes was defined as fasting blood
glucose greater than 126.13 mg/dL (to convert to millimoles per liter, multiply by 0.0555) or use of
antidiabetic medications or self-reported as having diabetes.33 Chronic kidney disease was defined as
eGFR less than 60 mL/min/1.73 m2. Depressive symptoms were considered as a score of 16 or higher
on the validated Center for Epidemiology Depression Scale.34
Statistical Analysis
EN-RAGE and S-RAGE were analyzed continuously, per SD increase of log transformed values
because of skewed distributions, and categorized into tertiles, with the lowest tertile as the
reference. Prior to analysis, outliers were excluded (defined as outside of the mean and 4 SDs range).
To assess the association of EN-RAGE and S-RAGE with dementia, we used logistic regression for the
cross-sectional analyses and Cox proportional hazard models for the longitudinal analyses. Follow-up
started when blood was drawn and ended at the date of dementia diagnosis, date of death, or end
of the study period (January 1, 2016), whichever came first. Follow-up until January 1, 2016 was near
complete (10 711 of 11 079 [97%] potential person-years). A timeline for data collection is shown in
eFigure 3 in the Supplement. Furthermore, we examined how these associations changed over
follow-up time by performing analyses in incremental periods of follow-up.35 Briefly, participants
who did not develop dementia were artificially censored at 4, 8, and 12 years; thus, the follow-up
periods vary as 0 to 4 years, 0 to 8 years, 0 to 12 years, and 0 until the end of follow-up. In addition,
we visualized overall survival during follow-up by EN-RAGE and S-RAGE tertile in Kaplan-Meier
survival curves.
Skin autofluorescence values were analyzed per SD difference (the equivalent of 0.49 AU), after
excluding outliers. Scores of the Stroop test were inverted; thus, higher scores for all cognition tests
correspond to better performance. Cognitive test scores were standardized and analyzed as z scores.
A parameter for general cognitive function, the G-factor, was calculated for participants with all test
scores available by extracting the first principal component from the test scores of Letter Digit
Substitution Task, Stroop (interference task), Word Fluency Test, Word Learning Test (delayed recall
task), and the Purdue Pegboard sum score.28 This calculation was based on data from 3955
Rotterdam Study participants who had completed the full battery of tests. The cross-sectional
associations of skin autofluorescence with the G-factor and with the individual tests were
investigated in linear regression models. Although it was not the focus of this study, we additionally
assessed the association of skin autofluorescence with prevalent dementia.
All analyses were adjusted for age, sex, and diabetes (model 1).1,2,36 Model 2 additionally
adjusted for other potential confounders, selected based on literature, namely educational level,
APOE ε4 carrier status, smoking behavior, and eGFR. To explore the association of covariates that are
potential confounders but which may be intermediates as well, we additionally adjusted for blood
pressure, high-density lipoprotein cholesterol level, total cholesterol level, triglyceride levels, lipid-
lowering medication use, and depressive symptoms in model 3.25,37-39
Stratification and Sensitivity Analyses
To evaluate potential association modification by sex and APOE ε4 carrier status, their interaction
with the AGE-RAGE markers was tested, and stratified analyses were performed. We also repeated
the analyses stratified by subcohort and after excluding participants with diabetes and with chronic
kidney disease to investigate whether these subgroups drove the associations. To evaluate whether
age was sufficiently adjusted for, we tested whether additionally adjusting for age squared changed
the results. Finally, we repeated the analyses restricting to dementia of the AD subtype.
Of all participants, 578 (15%) had at least 1 missing value (eTable 1 in the Supplement). Missing
data on covariates were imputed using 5-fold multiple imputation (ie, multivariate imputation by
chained equations package in R statistical software version 3.6.1 [R Project for Statistical
Computing]).40 Survival analyses were conducted using the survival package in R. All other analyses
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were conducted using R Studio version 1.0.153. Statistical testing was performed 2-sided with P < .05
considered significant. Data were analyzed June 2019 to December 2019.
Results
EN-RAGE, S-RAGE, and Dementia
Among 7983 participants of the Rotterdam Study, 4214 participants (mean [SD] age, 72.8 [7.4] years;
2465 [58%] women) visited the research between 1997 and 1999. Of them, 1021 (mean [SD] age,
73.6 [7.8] years; 564 [55%]) had data on EN-RAGE and S-RAGE levels and were included in this study.
For the cross-sectional analyses, 964 participants from the random subset with plasma data (mean
[SD] age 73.0 [7.5] years; 529 [54.9%] women; 16 participants [1.7%] with dementia at baseline) and
an additional 57 patients with dementia at baseline from the extended subset were eligible. The
mean (SD) age at dementia diagnosis was 79.9 (7.9) years. After excluding participants with prevalent
dementia and those without follow-up time, 945 participants were included in the longitudinal
analyses (eFigure 1 in the Supplement).
Baseline characteristics of all patients with dementia at baseline and of the study population at
risk for dementia are shown in Table 1. The value ranges for the EN-RAGE tertiles were less than 1.38
ng/mL in the lowest tertile, 1.38 ng/mL to 8.88 ng/mL in the middle tertile, and greater than 8.89
ng/mL in the highest tertile, and the teriles for S-RAGE were less than 2.15 ng/mL in the lowest tertile,
2.15 ng/mL to 3.22 ng/mL for the middle tertile, and 3.22 ng/mL or greater for the highest tertile.
Compared with low levels, high EN-RAGE levels were associated with higher dementia prevalence
(model 2 adjusted odds ratio [OR], 3.68 [95% CI, 1.50-8.03]; P = .003), and high S-RAGE levels were
associated with lower dementia prevalence (model 2 adjusted OR, 0.37 [95% CI, 0.17-0.78]; P = .01)
(Table 2). During a total follow-up of 10 711 person-years (median [interquartile range], 12.4 [6.2-16.3]
years), 161 participants developed dementia (mean [SD] age at diagnosis, 84.4 [6.0] years), of whom
130 participants (81%) developed AD. We found no significant difference in risk of incident dementia
among participants with a high EN-RAGE level compared with those with a low level (model 2
adjusted hazard ratio [HR], 0.65 [95% CI, 0.42-1.01]; P = .05), nor for participants with high S-RAGE
levels compared with those with low levels (model 2 adjusted HR, 1.22 [95% CI, 0.82-1.81]; P = .33)
(Table 2). There was no statistically significant interaction with sex or APOE ε4 carrier status (eTable 2
in the Supplement).
When analyzing in cumulative follow-up intervals from baseline, the risk of dementia for the
high EN-RAGE group was higher in the first years compared with the low EN-RAGE group. With
longer follow-up duration, this association of high EN-RAGE level diluted and even changed direction
(Figure 1A and C). A lower risk of dementia with higher S-RAGE level was found for a short follow-up.
However, with longer follow-up duration, this association also changed in direction (Figure 1B and D;
eTable 3 in the Supplement). The survival curves showed that participants with high levels of
EN-RAGE had lower survival than participants with medium and low levels. No differences in survival
were found for the S-RAGE groups (eFigure 4 and eFigure 5 in the Supplement).
Skin Autofluorescence and Cognitive Function
A total of 2890 participants who had undergone at least 1 of the cognitive tests and had a skin
autofluorescence measurement available were eligible for skin autofluorescence analysis (mean [SD]
age, 72.5 [9.4] years; 1640 [57%] women; mean [SD] skin autofluorescence, 2.40 [0.49] AU)
(Table 1). Characteristics by skin autofluorescence tertiles are presented in eTable 4 in the
Supplement, and details of tests are provided in eTable 5 in the Supplement. The G-factor explained
54.0% of the variance in cognitive test scores. Higher skin autofluorescence was associated with
lower general cognitive function (model 2 adjusted mean difference in G factor per 1-SD higher skin
autofluorescence, −0.07 [95% CI, −0.11 to −0.04]), and with the worse performance in individual
tests. The associations were stronger among individuals who were APOE ε4 carriers than among
noncarriers (adjusted difference in G factor among carriers, −0.15 [95% CI, −0.22 to −0.07]; P for
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interaction = .002) (Figure 2). In line with the results for cognition, we found that participants with
prevalent dementia had higher values of skin autofluorescence (eTable 6 in the Supplement).
Sensitivity Analyses
Similar results were obtained when using the alternative models for adjustment, including
adjustment for age and sex only, and stratified by subcohort (Table 2; eTable 7 and eTable 8 in the
Supplement). Exclusion of participants with diabetes or chronic kidney disease also did not change
the results (eFigure 6 and eTable 9 in the Supplement), nor did adjustment for age squared. The
results similarly did not change when restricting to dementia of the AD type (eTable 10 in the
Supplement).









At risk for dementia
(n = 945)
Age, mean (SD), y 82.5 (8.2) 72.9 (7.4) 72.5 (9.4)
Women 45 (62) 518 (55) 1640 (57)
White race 68 (96) 909 (98) 2675 (96)
Educational level
Primary 37 (51) 150 (16) 193 (7)
Lower 18 (25) 410 (44) 1120 (39)
Intermediate 14 (19) 292 (31) 871 (31)
Higher 3 (4) 85 (9) 662 (23)
APOE ε4 carrier status
No APOE ε4 allele 27 (40) 651 (72) 1977 (73)
1 allele 30 (44) 243 (27) 672 (25)
2 alleles 11 (16) 14 (2) 63 (2)
Alcohol use 37 (61) 766 (82) 2471 (86)
Smoking
Never 5 (8) 134 (14) 916 (32)
Former 26 (43) 474 (51) 1565 (55)
Current 30 (49) 328 (35) 373 (13)
BMI, mean (SD) 25.3 (3.3) 26.8 (3.9) 27.5 (4.3)
Blood pressure, mean (SD), mm Hg
Systolic 138.8 (21.9) 144.0 (21.5) 144.6 (21.5)
Diastolic 71.49 (11.0) 75.05 (11.0) 83.71 (10.8)
Total cholesterol, mg/dL 255 (41) 258 (46) 211 (42)
High-density lipoprotein cholesterol,
mg/dL
49 (15) 53 (15) 58 (17)
Triglycerides, median (IQR), mg/dL 88 (65-123) 85 (54-126) 113 (86-153)
Using lipid-lowering medication 3 (4.3) 118 (13.9) 877 (31)
Estimated glomerular filtration rate,
median (IQR), mL/min/1.73 m2
65 (52-80) 73 (64-83) 75 (66-84)
Chronic kidney disease 25 (36) 158 (17) 413 (15)
Diabetes 14 (20) 105 (12) 393 (14)
History of cardiovascular disease
and heart failure
10 (14) 59 (6) 266 (9.2)
Depressive symptoms 9 (21) 50 (6) 640 (22)
Plasma EN-RAGE, median (IQR), ng/mL 17.3 (11.8-22.2) 10.9 (7.8-14.8) NA
Plasma S-RAGE, median (IQR), ng/mL 2.2 (1.6-3.1) 2.7 (2.0-3.7) NA
Skin autofluorescence, AU NA NA 2.40 (0.49)
Abbreviations: EN-RAGE, extracellular newly identified
RAGE binding protein; IQR, interquartile range; RAGE,
advanced glycation end products receptor; S-RAGE,
soluble RAGE.
SI conversion factors: To convert total and high-
density lipoprotein cholesterol to millimoles per liter,
multiply by 0.0259; To convert triglycerides to
millimoles per liter, multiply by 0.0113.
a Values are shown for nonimputed data.
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Discussion
In this cohort study, we found that high EN-RAGE and low S-RAGE plasma levels were associated with
higher dementia prevalence. High EN-RAGE plasma levels were also associated with an increased
risk of incident dementia, but only for the short term. Tissue accumulation of AGEs, measured as skin
autofluorescence, was associated with lower general cognitive function and APOE ε4 carrier status
modified the association.
These results are in line with previous studies that reported cross-sectional associations of
S-RAGE, EN-RAGE, and dementia, and with smaller sample size studies on skin, circulating, and urine
AGEs and cognition.6,41,42 Our results suggest that the activation of RAGE by AGEs, EN-RAGE, or
other ligands may be involved in the pathophysiological processes of dementia. Since the found
associations were restricted to cross-sectional and short-term associations, reverse causation,
meaning the exposure was causally related to the outcome, cannot be ruled out. For example, altered
AGE and RAGE levels could be a consequence of lifestyle changes in the preclinical phase of
dementia. However, skin AGEs, reflecting long-term AGE load, were associated with cognition in
individuals without dementia, suggesting a role in cognitive decline. In line with this, we also found
that participants with dementia had higher values of skin autofluorescence.
If AGEs and their receptor are associated with the risk of dementia, several putative
mechanisms have been suggested, including disruption of the blood-brain barrier, facilitation of
amyloid-β into the brain, vascular pathological processes, and activation of inflammatory pathways
that subsequently leads to upregulation of RAGE expression.4,11,12,43,44 AGEs may also contribute to
neurodegeneration by mechanisms independent of RAGE, such as modification and cross-linking of
proteins, which may contribute to the toxic effects of amyloid-β,45 cellular damage and dysfunction,
tissue stiffness, vascular pathological processes, and formation of aggregates.2,3








Low 9/324 1 [Reference] 1 [Reference] 1 [Reference]
Medium 16/337 1.76 (0.74-4.19) 1.42 (0.55-3.64) 1.46 (0.55-3.85)
High 47/356 4.01 (1.86-8.68) 3.68 (1.50-8.03) 3.38 (1.42-8.04)
Per 1-SD increase 72/1017 1.80 (1.39-2.34) 1.74 (1.28-2.35) 1.67 (1.22-2.27)
Dementia incidence, HR
(95% CI)
Low 61/314 1 [Reference] 1 [Reference] 1 [Reference]
Medium 64/320 1.13 (0.79-1.61) 1.08 (0.76-1.55) 1.08 (0.75-1.56)
High 35/308 0.68 (0.45-1.05) 0.65 (0.42-1.01) 0.65 (0.42-1.00)




Low 35/346 1 [Reference] 1 [Reference] 1 [Reference]
Medium 20/341 0.54 (0.29-1.00) 0.56 (0.28-1.13) 0.61 (0.29-1.29)
High 17/333 0.50 (0.26-0.95) 0.37 (0.17-0.78) 0.35 (0.16-0.76)
Per 1-SD increase 72/1020 0.71 (0.55-0.92) 0.60 (0.45-0.81) 0.61 (0.45-0.84)
Dementia incidence, HR
(95% CI)
Low 51/309 1 [Reference] 1 [Reference] 1 [Reference]
Medium 54/321 0.93 (0.63-1.37) 1.04 (0.70-1.55) 1.00 (0.67-1.50)
High 56/315 1.09 (0.74-1.60) 1.22 (0.82-1.81) 1.15 (0.77-1.71)
Per 1-SD increase 161/945 0.94 (0.79-1.10) 0.94 (0.79-1.10) 0.95 (0.80-1.13)
Abbreviations: EN-RAGE, extracellular newly identified
RAGE binding protein; HR, hazard ratio; OR, odds ratio;
RAGE, advanced glycation end products receptor;
S-RAGE, soluble RAGE.
a Adjusted for age, sex, and diabetes.
b Adjusted for potential confounders (ie, age, sex,
diabetes, education, APOE ε4 carrier status, smoking
status, and estimated glomerular filtration rate).
c Adjusted for potential mediators (ie, systolic and
diastolic blood pressure, cholesterol, high-density
lipoprotein cholesterol, triglycerides, lipid-lowering
medication use, and depressive symptoms) in
addition to model 2.
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Because of the suggested involvement of RAGE in the pathological processes of dementia, and
especially because of its suggested role in amyloid-β influx into the brain, inhibition of the amyloid-
β–RAGE interaction was suggested to reduce the pathological processes of AD.46 Following this
reasoning, a phase 3 clinical trial was conducted with patients with probable mild AD with an
antagonist of RAGE but was ended earlier because futility criteria were met.47 However, whether
inhibition of RAGE has a role in the prevention of dementia cannot be concluded from these data.
Regarding the long-term associations of EN-RAGE, the higher risk of dementia was diluted,
especially in the high EN-RAGE group. Competing events, including mortality, may have concealed an
adverse association of EN-RAGE with dementia because the high EN-RAGE group showed high
mortality during follow-up and high EN-RAGE levels are associated with other diseases, such as
coronary heart disease.20
Regarding S-RAGE, it is important to mention that 2 types of this molecule exist, both
functioning as a decoy for RAGE ligands, that could not be distinguished by our measurement
method.48,49 One of them, cleavage RAGE, is derived from cleavage of membrane-bound RAGE and
is upregulated with RAGE activation. The second type is directly translated from alternative splicing
of RAGE mRNA, therefore called endogenously secreted S-RAGE. Aside from a protective anti-
inflammatory association, increased S-RAGE may therefore be a result of proinflammatory
upregulation of RAGE. Future studies may consider distinguishing between the 2 types in their
analyses or to focus on changes of levels over time to reduce this problem.
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Associations of plasma levels with dementia incidence per cumulatively increasing
duration of follow-up were obtained by censoring all participants still at risk at 4, 8, and
12 years after baseline, and after a total follow-up of 18.7 years. All estimates were
adjusted for age, sex, diabetes, education, APOE ε4 carrier status, smoking, and
estimated glomerular filtration rate. RAGE indicates Glycation End Products Receptor;
EN-RAGE, extracellular newly identified RAGE binding protein; S-RAGE, soluble RAGE;
HR, hazard ratio; and OR, odds ratio.
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We observed a modification for the association between skin autofluorescence and cognitive
function by APOE ε4 allele status, indicating that the AGE-RAGE system may participate in the
pathological changes associated with APOE. APOE ε4 is associated with altered glucose metabolism
in the central nervous system, and carriers of the APOE ε4 allele are more susceptible to stressors
and injurious agents.50 It is less effective in prompting the proteolytic breakdown of amyloid-β
aggregates and shows enhanced AGE-binding.51-54 In addition, differences in levels of AGE-RAGE
markers by APOE ε4 carrier status were found in individuals who were not cognitively impaired.55,56
Summarized, APOE ε4 and the AGE-RAGE system may have a joint association with the
pathophysiological processes of dementia.
Strengths of our study include the prospective design with a long follow-up, the extensive
assessment of cognition using a cognitive test battery covering several domains, and near-complete
dementia follow-up. Furthermore, skin AGEs were noninvasively measured in a large number of
individuals. They are considered a proxy for AGEs in long-lived tissue, potentially including the brain,
although no studies assessed their correlation.42
Limitations
Limitations of this study include the absence of repeated measurements for cognition to assess
cognitive decline, and of sufficient follow-up time for dementia after skin autofluorescence









G-factor –0.07 (–0.11 to –0.04)
LDST –0.06 (–0.09 to –0.03)
Stroop –0.05 (–0.08 to –0.01)
WFT –0.03 (–0.07 to 0.01)
WLT –0.06 (–0.10 to –0.02)
PPB –0.09 (–0.13 to –0.06)
Male participants
G-factor –0.05 (–0.10 to –0.005)
LDST –0.03 (–0.08 to 0.02)
Stroop –0.05 (–0.10 to 0.004)
WFT –0.03 (–0.09 to 0.03)
WLT –0.01 (–0.07 to 0.04)
PPB –0.10 (–0.16 to –0.05)
Female participants
G-factor –0.09 (–0.14 to –0.04)
LDST –0.09 (–0.14 to –0.04)
Stroop –0.04 (–0.09 to 0.01)
WFT –0.02 (–0.07 to 0.03)
WLT –0.10 (–0.15 to –0.05)
PPB –0.09 (–0.13 to –0.04)
APOE ε4 carriers
G-factor –0.15 (–0.22 to –0.07)
LDST –0.09 (–0.15 to –0.02)
Stroop –0.08 (–0.15 to –0.01)
WFT –0.03 (–0.11 to 0.05)
WLT –0.09 (–0.17 to –0.01)
PPB –0.14 (–0.20 to –0.07)
Noncarriers of APOE ε4
G-factor –0.05 (–0.09 to –0.01)
LDST –0.04 (–0.08 to –0.003)
Stroop –0.03 (–0.07 to 0.01)
WFT –0.03 (–0.07 to 0.02)
WLT –0.04 (–0.08 to 0.004)
PPB –0.07 (–0.11 to –0.03)
LDST indicates letter-digit substitution task; WFT,
verbal fluency test; WLT, word learning test (delayed
recall); and PPB, sum score Purdue pegboard tests,
including tests on left hand, right hand, and both
hands. The original score of the Stroop test
(interference task) was inversely transformed. After
transformation, a higher score corresponds to better
performance. Coefficients are the difference in
G-factor and z-scores of test parameters in association
with 1-SD difference in skin autofluorescence, obtained
from the linear regression adjusting for age, sex,
diabetes, education, APOE ε4 carrier status, smoking
status, and estimated glomerular filtration rate. For
subgroup analysis by APOE ε4 carrier status, APOE ε4
carrier status was not used in the model for
adjustment.
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measurement. In addition, we may not have been able to detect modification of the associations
between EN-RAGE and S-RAGE and dementia by APOE status, owing to small numbers within the
strata. Furthermore, EN-RAGE and S-RAGE have a complex role both within and outside the
AGE-RAGE system; therefore, they may not completely reflect the associations of the AGE-RAGE
system with dementia. The measurement of circulating markers is also a momentary capture of the
profile and may not adequately reflect the status later. Moreover, cardiometabolic risk factor
management may have changed over time, which may have impacted the 3 cohort waves differently,
potentially leading to bias. In this study, we were not able to examine the role of different diabetes
medications, owing to limited sample sizes. Future studies are encouraged to investigate their role.
Additionally, our results were restricted to an elderly population of European ancestry; future studies
including participants of varying ethnicities and of younger age may extend the generalizability of
the results.
Conclusions
The results of this cohort study suggest that the AGE-RAGE system was associated with the
pathophysiological processes of dementia. However, the association with the risk of dementia, if any,
was restricted to the short term. Studies are warranted to investigate the potential for the AGE-RAGE
system as a marker associated with future dementia.
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